Key result
Ziprasidone links to weight loss and favorable metabolic effects versus olanzapine, without QTc differences.
Why the study?
The metabolic and cardiovascular effects of ziprasidone versus olanzapine in adults with schizophrenia and other psychoses were not well characterized.
Does ziprasidone compared to olanzapine improve metabolic parameters and QTc interval in adults with schizophrenia and other psychoses?
Population
191 adults with schizophrenia and other psychoses
Comparison
Ziprasidone versus olanzapine
Design
Retrospective cohort chart review
Authors
Loading...
May inform antipsychotic selection to limit metabolic risk; leaves open need for prospective cardiovascular outcome trials.
Cohort (n=191)
Does ziprasidone compared to olanzapine improve metabolic parameters and QTc interval in adults with schizophrenia and other psychoses?
Ziprasidone has a more favorable metabolic and weight profile compared to olanzapine in patients with schizophrenia, with neither drug significantly prolonging the QTc interval.
Brown et al. (2005) conducted a cohort in Schizophrenia and other psychoses (n=191). Ziprasidone vs. Olanzapine was evaluated on QTc interval, weight, and metabolic parameters. Ziprasidone was associated with weight loss and favorable metabolic effects, whereas olanzapine caused significant weight gain (P<0.001) and adverse lipid and HbA1c changes, with no QTc differences.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: